People with cancer who were HIV-positive and received antiretroviral treatment based on protease inhibitors reported more adverse events than those treated with integrase inhibitor- or non-nucleoside reverse transcriptase inhibitor-based medications, an analysis found. Six-month efficacy of the protease inhibitor-based regimen was lower than with the other two treatment options. The findings were presented at the Interscience Conference on Anti-Microbial Agents and Chemotherapy.
Protease inhibitor risks may be greater for HIV-positive cancer patients
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan
|Vice President of Finance||
Urban Health Plan, Inc.
|Director of Payor/Provider Contracting||
U.S. Medical Management